US Distributor Demands Better Biosimilars Support
Removing legal hurdles and putting biosimilars on preferred formulary tiers will increase access and cut the cost of biologic therapies in the US, argues the chief of major healthcare distributor AmerisourceBergen.
You may also be interested in...
The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.
Assertions that the US should give up on supporting biosimilars in favor of controlling prices of off-patent biologic brands fail to recognize promising signs of progress, argues Richard Saynor, who has just taken over as CEO of biosimilars pioneer Sandoz.
Amgen’s Mvasi and Kanjinti alternatives to Roche’s Avastin bevacizumab and Herceptin trastuzumab brands will from 1 October be preferred by plans administered by the largest US health insurer, UnitedHealthcare.